← Oncology Approval Tracker

FDA DECISION ·

Wilserdly + everolimus

giredestrant and everolimus · Genentech

FDA approvalNew therapyBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Giredestrant with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, identified by an FDA-authorized test, after recurrence during or after adjuvant endocrine-based therapy or progression on a metastatic endocrine-based regimen.

SUPPORTING DATA

Evidence behind the decision

Study
evERA: randomized, open-label trial; 373 participants, including 207 with ESR1 mutations.
Key result
In the ESR1-mutated population, median progression-free survival was 10 versus 5.5 months against physician-selected endocrine therapy plus everolimus; hazard ratio 0.38 (95% CI 0.27-0.54).
Safety to report
FDA reports stomatitis, rash, fatigue, diarrhea and pneumonitis; warnings include bradycardia and embryo-fetal toxicity.
Evidence limits
Overall-survival data were immature. The trial does not support cross-trial comparisons with other endocrine combinations.

LAMPGEN ANALYSIS

Why it matters

A new oral endocrine combination for a molecularly selected population. Its approval does not establish benefit in earlier breast cancer settings.

What research teams should watch

Study teams should align ESR1 testing, prior endocrine-treatment records, progression dates and oral-treatment accountability before screening.

PRIMARY RECORDS

Sources